TNT Trial

John C. Larosa, Scott M Grundy, David D. Waters

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The link between elevated LDL-C levels and increased risk of coronary heart disease (CHD) events is well established. The primary hypothesis of Treating to New Targets (TNT) was that reducing LDL-C levels to well below 100 mg/dL (2.6 mmol/L) in stable CHD patients with modest LDL-C elevation could yield incremental clinical benefit. This hypothesis was tested by comparing the occurrence of major cardiovascular endpoints in two groups of patients: one that received 10-mg atorvastatin daily with the intent to reach an average LDL cholesterol target of approximately 100 mg/dL (2.6 mmol/L), and one that received 80-mg atorvastatin daily with the intent to reach an average LDL cholesterol of approximately 75 mg/dL (1.9 mmol/L). The results of the TNT study indicate that the linear relationship between reduced LDL-C and reduced CHD risk demonstrated in prior statin secondary prevention trials holds true even at very low LDL-C levels.

Original languageEnglish (US)
Title of host publicationConcepts, Principles, Trials, and Designs
Publisherwiley
Pages887-893
Number of pages7
Volume1
ISBN (Electronic)9781118596005
ISBN (Print)9781118595923
DOIs
Publication statusPublished - Sep 26 2014

    Fingerprint

Keywords

  • Coronary heart disease (CHD)
  • Treating to New Targets (TNT)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Larosa, J. C., Grundy, S. M., & Waters, D. D. (2014). TNT Trial. In Concepts, Principles, Trials, and Designs (Vol. 1, pp. 887-893). wiley. https://doi.org/10.1002/9781118596005.ch75